Most patients should receive metformin initially, but if control is suboptimal after 36 months, treatment intensification with another glucose-lowering therapy is required, and selection of subsequent therapies should be made on an individualized basis to meet the specific needs of the patient (4)
J Clin Invest 1993;91:301307.ArticlePubMedPMC 86
Notably, the STEP TEENS trial showed that semaglutide 2.4 mg, administered once weekly via subcutaneous injection, can be used in individuals aged 12 years and older, as adolescents with obesity treated with semaglutide experienced a significant reduction in BMI compared with placebo, along with improvements in several cardiometabolic risk factors [47]
Content about nausea, constipation, appetite changes, or dose escalation remains educational and does not replace care from a licensed clinician
Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients